Update the URLs for Novavax press releases

Nice going changing URLs to things that people want to refer to for a long time, cool!
ljl-covid · Oct 15, 2021 · 875c2ef · 875c2ef
1 parent 9f91e13
commit 875c2ef
Showing 1 changed file with 2 additions and 2 deletions.
diff --git a/README.md b/README.md
@@ -379,9 +379,9 @@ Note that the WHO will generally be unable to make statements that their more pr
 
 #### Novavax (NVX-CoV2373)
 
-* [Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3), as announced in a press release by the company about their NVX-CoV2373 protein-based vaccine, based on a trial that included 27% over the age of 65, and on an interim analysis after 62 cases developed, of which 56 were in the placebo group; at the same time, [Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant](https://www.medrxiv.org/content/10.1101/2021.02.25.21252477v1) in South Africa was 60% (among HIV-negative individuals), likely due to 90% prevalence of the South African escape variant, which the company says has initiated development of boosters for
+* [Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial](https://ir.novavax.com/2021-01-28-Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial), as announced in a press release by the company about their NVX-CoV2373 protein-based vaccine, based on a trial that included 27% over the age of 65, and on an interim analysis after 62 cases developed, of which 56 were in the placebo group; at the same time, [Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant](https://www.medrxiv.org/content/10.1101/2021.02.25.21252477v1) in South Africa was 60% (among HIV-negative individuals), likely due to 90% prevalence of the South African escape variant, which the company says has initiated development of boosters for
 * [Novavax announcement of UK and South AfricaTrial Results](https://www.novavax.com/sites/default/files/2021-01/UK-SouthAfrica%20-Trial-Results.pdf) is fairly boasting ("breaking news", seriously?) but contains a lot of nice infographics and variant spread graphs
-* [Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and) with 29,960 in the United States and Mexico, among which 63 cases of COVID were seen in the placebo group and 14 in the vaccine group, and the efficacy appears to remain high in patients with sequenced variants of concern
+* [Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial](https://ir.novavax.com/2021-06-14-Novavax-COVID-19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial) with 29,960 in the United States and Mexico, among which 63 cases of COVID were seen in the placebo group and 14 in the vaccine group, and the efficacy appears to remain high in patients with sequenced variants of concern
 
 
 #### Others